Effects of defibrotide on peripheral obliterative vascular diseases.
Twenty-nine patients with atherosclerotic obliterative vascular disorder and 9 cases of Buerger's disease were treated with 600 mg defibrotide daily for 10 days and then three times weekly for 3 months. The response to therapy was evaluated from hemostatic parameters, venostasis test (cuff test), treadmill testing, and radionuclide arteriography. We observed increased pain-free intervals in daily life and during treadmill testing. There was also a significantly higher response in the cuff test and improved perfusion as seen by radionuclide arteriography.